(2R,4R)-tert-butyl 2-((1S,2S)-2-amino-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)-4-propoxypyrrolidine-1-carboxylate | 910447-82-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,4R)-tert-butyl 2-((1S,2S)-2-amino-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)-4-propoxypyrrolidine-1-carboxylate
• 英文别名: tert-butyl (2R,4R)-2-[(1S,2S)-2-amino-1-[tert-butyl(dimethyl)silyl]oxy-3-(3,5-difluorophenyl)propyl]-4-propoxypyrrolidine-1-carboxylate
• CAS: 910447-82-4
• 化学式: C₂₇H₄₆F₂N₂O₄Si
• 分子量: 528.756
• InChiKey: OZIPGJDTQJUCFE-QPXUXIHVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.03
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2R,4R)-tert-butyl 2-((1S,2S)-2-amino-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)-4-propoxypyrrolidine-1-carboxylate 在 N-甲基吗啉 、 盐酸 、 HATU 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-2-((R)-3-acetamido-3-isobutyl-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-propoxypyrrolidin-2-yl)propan-2-yl)-4-phenylbutanamide
  参考文献：
  名称：

  Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE)

  摘要：

  The synthesis, evaluation, and structure-activity relationships of a class of gamma-lactam 1,3-diaminopropan-2-ol transition-state isostere inhibitors of BACE are discussed. Two strategies for optimizing lead compound 1a are presented. Reducing the overall size of the inhibitors resulted in the identification of gamma-lactam 1i, whereas the introduction of conformational constraint on the prime-side of the inhibitor generated compounds such as the 3-hydroxypyrrolidine inhibitor 28n. The full in vivo profile of 1i in rats and 28n in Tg 2576 mice is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.109
• 作为产物：
  描述：

  (2R,4R)-tert-butyl 4-(allyloxy)-2-((1S,2S)-2-(benzyloxycarbonylamino)-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)pyrrolidine-1-carboxylate 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 生成 (2R,4R)-tert-butyl 2-((1S,2S)-2-amino-1-(tert-butyldimethylsilyloxy)-3-(3,5-difluorophenyl)propyl)-4-propoxypyrrolidine-1-carboxylate
  参考文献：
  名称：

  Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE)

  摘要：

  The synthesis, evaluation, and structure-activity relationships of a class of gamma-lactam 1,3-diaminopropan-2-ol transition-state isostere inhibitors of BACE are discussed. Two strategies for optimizing lead compound 1a are presented. Reducing the overall size of the inhibitors resulted in the identification of gamma-lactam 1i, whereas the introduction of conformational constraint on the prime-side of the inhibitor generated compounds such as the 3-hydroxypyrrolidine inhibitor 28n. The full in vivo profile of 1i in rats and 28n in Tg 2576 mice is presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.109

文献信息

• Novel isophthalates as beta-secretase inhibitors
  申请人：Thompson A. Lorin

  公开号：US20060229309A1

  公开（公告）日：2006-10-12

  There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R 3 , R 5 and R 6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列取代的异苯二甲酸酯化合物(I)或其立体异构体；或其药学上可接受的盐，其中W、R3、R5和R6如本文所定义，以及它们的药物组合物和使用方法。这些新化合物抑制β-分泌酶对淀粉样前体蛋白(APP)的加工，更具体地抑制Aβ肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生有关的神经系统疾病，如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的疾病的化合物。
• Isophthalates as beta-secretase inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US07745470B2

  公开（公告）日：2010-06-29

  There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供了一系列取代的异苯二甲酸酯化合物，其化学式为(I)或其立体异构体；或其药学上可接受的盐，其中W、R3、R5和R6的定义如本文所述，还提供了这些化合物的制药组合物和使用方法。这些新型化合物能够抑制β-分泌酶对淀粉样前体蛋白(APP)的加工作用，更具体地，它们能够抑制Aβ肽的产生。本文披露的化合物可用于治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的疾病。
• NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS
  申请人：Thompson, III Lorin A.

  公开号：US20100222581A1

  公开（公告）日：2010-09-02

  There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R 3 , R 5 and R 6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

  提供一系列式(I)的取代异苯二甲酸酯或其立体异构体；或其药学上可接受的盐，其中W、R3、R5和R6如本文所定义，以及它们的药物组合物和使用方法。这些新化合物抑制β-分泌酶对淀粉样前体蛋白(APP)的加工，更具体地，抑制Aβ肽的产生。本公开涉及用于治疗与β-淀粉样蛋白产生相关的神经疾病，如阿尔茨海默病和其他受抗淀粉样蛋白活性影响的病症的化合物。
• WO2006/99352
  申请人：——

  公开号：——

  公开（公告）日：——
• Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE)
  作者：Kenneth M. Boy、Jason M. Guernon、Jianliang Shi、Jeremy H. Toyn、Jere E. Meredith、Donna M. Barten、Catherine R. Burton、Charles F. Albright、Jovita Marcinkeviciene、Andrew C. Good、Andrew J. Tebben、Jodi K. Muckelbauer、Daniel M. Camac、Kimberley A. Lentz、Joanne J. Bronson、Richard E. Olson、John E. Macor、Lorin A. Thompson

  DOI：10.1016/j.bmcl.2011.06.109

  日期：2011.11

  The synthesis, evaluation, and structure-activity relationships of a class of gamma-lactam 1,3-diaminopropan-2-ol transition-state isostere inhibitors of BACE are discussed. Two strategies for optimizing lead compound 1a are presented. Reducing the overall size of the inhibitors resulted in the identification of gamma-lactam 1i, whereas the introduction of conformational constraint on the prime-side of the inhibitor generated compounds such as the 3-hydroxypyrrolidine inhibitor 28n. The full in vivo profile of 1i in rats and 28n in Tg 2576 mice is presented. (C) 2011 Elsevier Ltd. All rights reserved.